Curated News
By: NewsRamp Editorial Staff
November 17, 2025
Alpha Cognition's ZUNVEYL Shows 102% Growth in LTC Channel
TLDR
- Alpha Cognition's ZUNVEYL shows strong commercial momentum with 102% pharmacy order growth and expanding to 600+ nursing homes, offering investors potential advantage through projected profitability by 2027.
- Alpha Cognition's commercialization strategy focuses on long-term care channels with sequential pharmacy order growth, expanding prescriber base, and reduced operating spend guidance to achieve profitability targets.
- ZUNVEYL's expansion across nursing homes and development of treatments for cognitive conditions improves patient care and addresses neurological disorders, making healthcare more accessible for vulnerable populations.
- Alpha Cognition's patent extends ZUNVEYL protection to 2044 while DoD-funded research shows reduced neuroinflammation in brain injury studies, highlighting innovative neurological treatment approaches.
Impact - Why it Matters
This development matters because Alzheimer's disease and related cognitive disorders affect millions of patients and their families worldwide, creating an urgent need for effective treatments. Alpha Cognition's accelerating commercial success with ZUNVEYL demonstrates real-world adoption and physician confidence in a therapeutic area where treatment options remain limited. The company's expansion into more than 600 nursing homes and growing prescriber base indicates that healthcare providers are finding value in this medication for their patients. Furthermore, the research pipeline advancements, particularly the promising results in traumatic brain injury and development of alternative formulations for patients with swallowing difficulties, suggest broader potential applications beyond Alzheimer's disease. For investors, the combination of strong commercial momentum, extended patent protection to 2044, and substantial financial runway positions Alpha Cognition as a company worth watching in the neurodegenerative disease treatment space.
Summary
Alpha Cognition Inc. (NASDAQ: ACOG) is demonstrating significant momentum in its commercialization of ZUNVEYL®, with Stonegate Capital Partners updating their coverage on the company's impressive second quarter launch performance. The pharmaceutical company reported accelerating adoption across the U.S. long-term care channel, with pharmacy orders growing 102% sequentially and record prescription volumes each month. The brand's expansion now reaches more than 600 nursing homes, supported by a growing prescriber base exceeding 500 clinicians. Management's long-term care call strategy continues to drive durable adoption and repeat ordering behavior as ZUNVEYL becomes more embedded in high-volume facilities, reinforcing the medication's differentiated cognitive and behavioral profile alongside favorable tolerability in real-world use.
Financially, Alpha Cognition generated $2.8 million in total revenue for the third quarter of 2025, including $2.3 million in net product revenue from ZUNVEYL and $0.5 million in business development and licensing revenue. Year-to-date revenue reached $7.4 million, reflecting the company's successful market entry. The commercial team is deepening engagement with prescribers while expanding coverage within Medicare and LTC pharmacy networks to sustain prescription growth. Management has reduced operating spend guidance to $28-30 million and maintains its target for operating profitability in 2027. The CMS collaboration provides a crucial pathway to develop and commercialize ZUNVEYL across the Asia-Pacific region, potentially generating ex-U.S. revenues as early as fiscal year 2026.
Beyond commercial success, Alpha Cognition is building a broader neurodevelopmental disorder platform around ZUNVEYL and ALPHA 1062. Research and development achievements include promising results from a Department of Defense-funded Bomb Blast preclinical study in repetitive mild traumatic brain injury, showing reduced neuroinflammation and neuropathology. The company is advancing a sublingual ALPHA 1062 formulation for patients with dysphagia or aphasia, targeting formulation completion and taste testing in the first quarter of 2026. A recently granted U.S. patent extends ZUNVEYL protection to 2044, significantly strengthening the company's intellectual property position. With $73.2 million in pro forma cash following an October 2025 equity offering and a $75 million ATM facility, Alpha Cognition has substantial financial runway to support its growth initiatives and research pipeline.
Source Statement
This curated news summary relied on content disributed by Reportable. Read the original source here, Alpha Cognition's ZUNVEYL Shows 102% Growth in LTC Channel
